768:, yes there are positives to being focused. But there are degrees of being focused. At the outer extreme, there's the "Medication prices can be included when appropriate sources are avaliable" question that James offered a while back, which considers only the big "should we do this" but not "can we do this while following policy as Wikipedians" and leaves out the question of what sources are appropriate and when and what kind of statements we can make from them. At the other end of specific we could get a question about whether and when records in a database can be considered representative of the developing world. And that's a good question to discuss but only one of many and very specific to one database. If we agree, for example, that the median supplier price of a record with three or more suppliers is representative of the developing world, that doesn't permit all the other crimes against policy and guideline with that database, or other databases. It is perhaps too small a step, though one that needs to be taken.
1109:. It very much argues against the use we are doing, and why their sole focus on DDD is for utilisation. And yes at a crude population level, it could give a rough idea of the cost of utilising that drug in a specific formulation. That's up to researchers to judge if it meets their needs, not Wikipedians. What it doesn't represent, is the dose that an individual patient might take and thus cost them per day or month. Repeatedly MSH and WHO have to remind us it is not a therapeutic dose nor does it represent average prescribed doses (which themselves vary from country to country and year to year) . Wrt your second example, yes WHO give that as an example of how it could be used to compare the cost of e.g. 5mg tablet vs 10mg/5ml syrup. But, if you think about it for a moment, all you are doing with that is agreeing on an arbitrary dose to compare two formulations: the actual dose need not be representative of any therapeutic value. It's just a number.
1045:, has a problem. The source says "The cost of a 12-week course of sofosbuvir is as high as US$ 84,000 in the US". Our article might also say "as high as" rather than "about", because they mean different things. The date of the US price is "accessed Dec 2015" so that price isn't "as of 2016". "As-of" date inflation is the norm for drug prices, and I don't know why. The paper says "Branded sofosbuvir is available at a suggested price of US$ 900/12-week course in 101 named low-income countries" but the $ 900 figure isn't in the article sentence. The prices for UK, Canada and India claim to be sourced to this article, but are not. So of the first four drug prices you suggest could be included in an RFC, three of them are simply unsourced, and a chance to include the price for 101 low-income countries is not taken. ---
733:. The one WAID mentions is closed to #3 in my list and is certainly a very important one about whether the source supports the "in the developing world" claim in the text. However, that is also a question unique to one database and one world area, and doesn't help when we consider US, UK or other regions. Another important question is the degree to which original research is permitted to calculate a daily dose or treatment cost, especially when the source (nor other similar databases) does not say what strength of tablets to pick, how many to take a day and how long to take them for. Or whether picking one pill or one vial or one tube of cream, out of multiple options, is acceptable and representative. And so on. There are
2476:. So, in which order do we proceed now? It is my opinion that WAID has a well-crafted RFC, while the alternative needs considerable work towards refinement, and the experience of WAID to turn it into something less confusing. But yes, there is a risk we are approaching this in the wrong order. I dunno; I am hoping Barkeep has an approach to AN that will help sort all of the different factors, but including that we don't know how many editors were misled for four years. Add to that the OTHERCRAPEXISTS meme that even FAs have prices (some of which are compliant with NOTPRICE, and some of which shouldn't even be FAs, I say with former FAC delegate hat on), and we have lots to sort.
2280:, I hear you. When I first started trying to mediate this, I thought similarly and looked for the status quo version to roll this back to you. However, I have become convinced through education by those with institutional memory and lots of reading that this dispute goes back years and, at various times, there has been more support for including pricing information. Knowing that an RfC has been promised it's possible that some number of those who are in favor have not participated, especially as this page grew and grew and grew in length. I don't think anyone, on any side of this disagrees that WP:NOT plays an important role in this discussion. Best,
1113:
health disorders), the DDD is totally useless because the cost to treat really depends on what indication you are treating, and you don't know that. DDD is a red herring. Our only source that offers it (MSH) warns about its careful use and does not themselves use it to give a cost-per-day, which should be a clear warning sign that this is inappropriate original research. The other sources (Drugs.com, BNF, NADAC) do not give a DDD or indeed any one dose, so any attempt to use them to give a cost per day/month/treatment is both original research and synthesis of sources. --
2375:, well, the junk essay was certainly a problem, saying "There's no policy on prices" when, well, there was one. I'm generally in favor of giving wide latitude on essays, but that stops at blatant factual inaccuracies, and "There is no policy on prices" is factually false when, well, there most certainly is one. But I think that's a bit backwards. If the determination is that we shouldn't include prices at all, the question of sources for them becomes entirely moot. It's only if we determine they should be that we even have to care about how to source them.
1574:$ 10". Or they might say not to combine the DDD with the MSH's price per pill with the Canadian source about using the DDD this way, and tell us to just use the price per pill. They might even tell us to omit the dollars-and-cents and instead search for a source that would let us write "generally considered inexpensive". They might tell us all sorts of things. But again, all this is "answering the question", and the goal on this page today is only to write the question. Answer the question next week, please, and on the other page.
1417:
these prices), then argue the case when the RFC is posted. There is a reason why WHO/HAI have only 14 core global medicines and survey at most 50 (at specific strengths and formulations for specific indications and patient age and specific treatment duration or daily dose). The MSH database is way too sparse to be a reliable source for 500+ medicines. It is officially not a reliable source for international reference price if there are not many suppliers. That's WHO/HAI official policy. Which trumps any
Wikipedian opinion. --
1450:
you are fully engaged with us in sorting out these problems. We have this split now between the sample price discussion above of chlorthalidone, and this section; let's continue here. Do you now see that what we have presented to our readers for chlorthalidone, in the lead of an article, is neither useful nor accurate nor in accordance with NOR ? Sorting out that we have a big problem in 500+ articles is a very different matter than deciding via RFC whether drug prices from databases should even be in our articles at all.
1292:, and I'm not sure forbidding pings will help us move forward. Do you read all posts here, or do we have to ping you to each post? I ask because I really hate this pingie-thingie myself; when I come to a page I participate in and follow, I pull up a diff of everything since I last read, and the extra pings are just an irritation. Do we need to ping you, and if we are trying to sort out the price data in our drug articles, how can we assure you see the discussions if Colin is forbidden from pinging you?
2000:, my thoughts on your second suggested question ("Do you believe it is possible to provide a rough price for an amount of medication in LMIC?") is that the question is too general for other editors to grapple with. I can tell you my own answer (i.e., I believe it's possible to do this at the wholesale but not retail level, for some but not all drugs, and that most articles could be improved), and I believe that at this point, my answer has more factual and policy basis than the beliefs of : -->
888:
described. I'd probably trim the discussion around each example. For the section headings for the comments, I would select headings that target the key issues, like geographic scope and timeliness of the data, and let commenters discuss how the different
Knowledge principles should be weighed against each other in context of an issue. For instance, how should the encyclopedic value of having some information be balanced against the age of the data, and how many geographic regions does it cover?
836:. When that RFC came up, I took one look, and ran the other direction. I never participated. With too many options, people won't engage. (Obviously, I went too far the other direction with the singular "is it in sync" question at the MEDLEAD RFC.) The lengthy GMO RFC is what leads me to believe that the approach you took is best-- in between the two extremes, and written in a way that it draws the reader in and encourages participation rather than voting.
359:
your question, about adding these three examples to the others, I guess it would depend on what the question was. As I understood it, the issue in dispute, at least the one to be handled by an RfC, was just about how to use IMPPG as a source. There are a lot of other issues (and other sources) we could discuss about prices and pricing in general, and those three seem like good examples for that conversation (for some of the reasons pointed out below).
35:
940:
tablet" or "per vial" ... I can't really see how the reader can extract meaning from that unless we state that you take two 50mg tablets three times a day for 7 days, or that the vial is 10ml and a shot is 7ml, etc. And our MEDMOS policy has always been to avoid giving dose information. Perhaps that's MoS but it is also "is this encyclopaedic" -- a fact that one can't use meaningfully. Not sure where that goes. --
936:
aren't options and I think the discussion will need some structure lest it just be a sprawling mess. For example, the question of when/whether the source becomes representative of developing world is "statistics" and less about any wiki policy, but the question about pricing "per dose" when the source doesn't mention which strength and how many tablets to take each morning and night, is WP:V mixed with WP:OR.
738:
question is as helpful. Compare to 3D "Should articles state any pricing information cited to the
International Medical Products Price Guide". That invites a yes/no response, or some vague "Yes, sometimes or "No, only sometimes", and isn't actually being contested by anybody in the dispute. It leads away from looking for policy answers and rather more towards some advocacy answer and wishful optimism. --
1873:
DDD) so no there is not a straightforward calculation. The drug may be once a day or twice a day or some other option, and this may depend on what kind of tablet you take. These are all things a doctor will decide at prescription time. The most you can do, James, is convert a price per day to a price per month, assuming it is obvious the indication requires long-term treatment, of course. --
684:, 3A, 3B, and 3C in Levivich's draft are about sourcing content to drug price databases. Doc James' three suggested additions at the top of this section, however, are sourced to a journal article, a British newspaper, and a non-profit organization's website. It would not be logical to ask "Can we use drug price databases?" and then give an example of something that is sourced to
1544:
covers us if we give a price to four significant figures. It is one thing if our sources use that language, but it isn't a sticking plaster for dodgy maths. They may look at treatment X and treatment Y and conclude that treatment Y is 2x or 4x more expensive than X whereas in fact the difference in price is down to the random chance of original research. Btw, at
2338:
the community supports pricing in articles, and find out that the community does support drug prices in articles, does that endorse these databases being used? We have to get this question addressed first. Also, when I was digging around to sort all of this out, it was quite disconcerting to find that we had redirects away from NOT (
1524:
problem not only of LEAD, NOTPRICE and WEIGHT, but a problem of SYNTH. Do you see why we need a separate RFC on that matter before we move on to the wider RFC? How can we ask
Knowledge editors whether price information should be included, when we do not even have price information that we all agree conforms with other policy ?
2190:
disallowed pings), I tried to start over and go through an example with him. We can probably close this off now; I hope we can see that the first (WAID) RFC is not without merit, and there really is a need to consult the community on how to use these sources, since we got no response from the NOR noticeboard.
2346:, that earlier pointed to NOTPRICE)) to an essay, and the first line of that essay stated that Knowledge had no policy on prices. That misleading info stood for four years (I corrected it last week). So how do we know how much of the community was misinformed by a changed redirect that pointed at faulty info?
1218:
we see that if we did try to use the DDD, we get yearly prices of $ 90, $ 149 and $ 182 depending on which tablet size we chose. All three tablet sizes make sense for individual patients and indications and stages of treatment. This is why we don't allow original research: the numbers are effectively random. --
2431:
And if other editors agree with you that, e.g., the price of WHO Essential
Medicines (whose "essentialness" is partly a factor of their low cost) aren't "exceptional", then eventually we would remove those prices. In between now and then, it's IMO better to leave well enough alone than to guess that
1687:
I am saying we don't have sources to back up the information we are giving our readers without using SYNTH, and our personal opinions, what we have experienced or seen as physicians or people interpreting for physicians, should not be coming in to play at all. We do not have sources that back up the
1543:
James, mathematically, you cannot say "the wholesale cost is about US$ 13.50 a month" if you feel the price is only accurate to within 2x or 4x approximation and you don't care if 12.5mg, 25mg or 50mg tablets are used. Our readers trust what we write and really no amount of "about" or "approximately"
1449:
who understand the sources and understand SYNTH. The problems we have now in more than 500 articles go way beyond what an average reader, or even RFC respondent, can understand. Diverting energy now towards addressing those problems is a distraction from the RFC. But, we must continue to make sure
1257:
No, I'm saying that original research produces random numbers. The source gives three pill sizes and none of them are 37.5mg or 18.75mg. You say we should use DDD and then you cite a paper that looked at the DDD of 37.5mg and went ??? that's not gonna work and picked 50mg instead. Decisions decisions
1217:
we see the 6.25, 12.5 and 25mg tablets "twice a day" being the initial and then tritrated "if tolerated" up to the maximum, but lots of other dose options too. That really isn't the paper to convince anyone that DDD is a useful measure, when they don't use the DDD of 37.5mg but instead 50mg. Further,
1208:
tablet has no suppliers and a median buyer price of 0.2041 which is pretty close to the "average price per tablet of $ 0.20" they mention. But wait, 25mg doesn't go into 37.5mg, and they mention "twice daily treatment" so I guess they mean 50mg per day. That price is twice a day x 365 which is $ 149.
1073:
There has been a fair bit of discussion on whether or not DDD is appropriate for rough estimates of medication prices. We have a number of sources which support this use. Specifically the government of Canada says the DDD can be used to provide "a rough idea of the daily cost of utilizing a drug in a
930:
made. Brevity is good. In that vein, I'd drop the whole "We're going to try to.. in separate sections" bit. People will see the sections, and the "other" bit, and work it out for themselves and and nobody reads the instructions anyway. I'd drop the leading "The thing I really like" and "The problem I
891:
Nonetheless, I appreciate that my opinion is just one person's, and a lot of work has gone into building a consensus for the current draft. If consensus holds for the present format (or a slightly tweaked version), that's great! I don't feel the RfC should be held up if most people are happy with the
661:
to a database, rather are sourced in ways that appear to be in accordance with NOTPRICES. My concern with the (good) work done by
Levivich continues to be that we are not giving enough information to draw in the reader, encourage them to participate, or understand what question is being asked, all of
552:
Indeed, in fact an RFC on this doesn't need to happen at all, based on current evidence I've seen. Those are exactly the sort of drug-cost comments that are supported by policy and we generally get right. They are mentioned because they are exceptional and notable. Folk can argue about the merits per
2415:
should not include pricing information; that's why it's notable. There was another example I can't recall right to hand of a single treatment that costs over $ 2 million, and that price has similarly been extensively covered in reliable sources. We should include that there. In the
Shkreli incident,
2129:
Your source does not say what string you searched with. If I search with "Carvedilol" I get prices less than $ 0.05 per tablet, though the source does not say if one "tablet" equals one "dose", nor that I need to take that twice a day (so costing me twice as much). If I search with "Carvedilol ER" I
1872:
it isn't a simple calculation to convert. Firstly the sources don't give a price per "dose" either. They give a price for one tablet size or another. Even if we thought DDD was acceptable (which WHO, who invented it, don't) it doesn't necessarily divide into specific tablet sizes (see above for 37.5
1604:
most of the time we have no idea how the qualifies affect claims of benefit as they have just not been studied. But these still not prevent use from providing an overview. Yah sure MSH is not as good when there are fewer supplies. Same as a meta analysis is not as accurate when their are fewer RCTs.
1603:
Generally there is one main indication and regardless typically most if not all indications generally use similar doses. Most medication have a fairly narrow dosage range. Some of the sellers offer the medication in more than LMIC 100 countries. Qualifiers applies to all evidence within medicine and
1561:
On all of this about the "rough estimate": Editors who are responding the RFC are welcome to express opinions about whether the example sentences would be clearer if they included words like "rough estimate". Editors might advise us, for example, that the current examples aren't great, but that if
887:
I'm not exactly sure what SandyGeorgia is referring to by "..presented with too many options, and lengthy TOC". However as I discussed before, if it were solely up to me, I'd move the "In the real world" section up and expand it a little to lay out the specific key issues that Colin and WhatamIdoing
693:
IMO the locus of the immediate dispute is not "Can we include any prices at all?" or even "Can we use drug price databases at all?" The locus of the dispute is much closer to "Can editors pick any record they want in a drug price database, and generalize the contents to a statement about the entire
2337:
and my concern was, in what order do we approach these issues (NOT, DUE, LEAD, WEIGHT) when it became apparent we didn't even have a policy-compliant (NOR) example to put forward (in the opinion of those who believe the samples are not CALC, rather OR). If we put forward a RFC just to determine if
1982:
for years and years and years, and the appetite in the community for putting easily vandalized dosage numbers into articles has basically been zero. Let's please not try to change that rule today. (I'm willing to talk about that later, and I even have some ideas about how to manage vandalism, but
1926:
I think Nil Einne (above, collapsed) has a point. Most of this involves one party making a claim and then another party disagreeing. We can do that in the RFC. I think this should wait till the RFC, when other voices can chip in with support or rejection and hopefully a consensus form. There's zero
1773:
So do you see that we have a policy disagreement as to whether this is simple math without synthesis that needs to be put forward in an RFC, because we got ZERO feedback on the matter when we posted a question to the NOR noticeboard? And that we need to sort that out before we can solve the bigger
1469:
After our discussion what I see is that what we have in our article on chlorthalidone is a perfectly reasonable estimate of the price per month of the medication in question. Looking at the references yes 12.5 mg can be used, 25 mg can be used, and 50 mg can be used. Could the price range from 6.75
1416:
What matters isn't so much right now these abstract questions, which are complicated to answer, but actual sources and actual texts in actual articles, which despite months of discussion have not changed. If you believe these things are possible, and possible generally for most drugs (over 500 have
1412:
James, these aren't yes/no questions that apply in all cases. We can find drugs with one standard dose and we can find drugs with many suppliers in the MSH. But in the general case, no you can't. There are multiple indications, multiple dose ranges, multiple patient ages, weights and liver function
1287:
On the big picture, we have (mis)spent a lot of bandwidth on this talk page trying to sort out the various problems (SYNTH, NOR, WEIGHT) in price text in our drug articles. We went down that path when we (I?) were (was?) seeking one good example of drug pricing information from these databases that
1191:
James, it is so "rough" because it is for population studies. The kind where someone says we might spend £1.5 million on a drug, but it probably doesn't change the point if the actual cost is £1 million or £2 million. Knowledge is giving a price in dollars and cents for one patient, and then waving
737:
of questions and I think the beauty of WAIDs RFC is it allows editors to think about however many they want. They can concentrate on WP:V or WP:OR or WP:WEIGHT or WP:NOT or WP:LEAD. As soon as we ask a specific question and just that question, then it isn't so powerful, and I don't think a "should"
1548:
we give a "wholesale cost per dose". What does "per dose" mean? The dictionary tells me it is how much you take at one moment of time. So a DDD of 50mg but taken twice a day would produce a 25mg dose, but in a once a day sustained-release tablet would produce a 50mg dose. I don't think there's any
792:
I appreciate that different editors want to look at different questions, and so that's how the current draft RfC has ended up how it is. I have similiar concerns as
Tryptofish regarding the quality of feedback that may be received (though I don't share the worry about having just one RfC) and it's
358:
Oh, I meant those (3A, 3B, 3C) as alternative RfCs, not as three questions in one RfC–i.e., we'd only have ran one of those three, with one set of examples. Originally it was just 3A, but I added 3B and 3C in response to WAID's concerns above, and then 3D as an entirely different format. To answer
2416:
price was the main issue, extensively discussed by reliable sources, and so the article must include information about it. But for general articles about products, drugs or otherwise, where the price is mentioned but not especially significant? That's exactly what NOPRICES is meant to exclude. In
2189:
My reasoning: there is resistance on this page to launching WAID's RFC, and I am working to build understanding that there is a logical reason why we need that RFC before a broader one. Realizing the possibility that James was not following all of the discussion here earlier (possibly because of
1112:
Furthermore, there are no sources saying what indication the DDD was calculated for or what choice they made if their own source lacked a clear "maintenance dose" value (they sometimes pick initial and sometimes max). When we have a drug for multiple conditions (epilepsy, neuropathic pain, mental
935:
which may even merit being quote boxed). I think section headings should drop the "Comments about" prefix, as the whole thing is in a discussion section. I agree that having lots of options is really bad per the GMO one and because options force people to pick one and vote. These section headings
952:
This is a mess. If I am understanding correctly, we are now discussing WAID's proposed RFC in
Levivich's draft section, so who knows where we stand and who's on first. I could have it completely wrong; if we are in fact still discussing Levivich's drafts, could someone clue me in? It is time to
1523:
I chose chlorthalidone as a starting example because it is the one of the simplest I have seen in these discussions; the text we have presented on other drugs has far bigger problems. It is your opinion that our readers can sort it out. It is my opinion (and others) that what we have here is a
1337:
The next question than becomes one of knowledge parity. The popular press generally just writes for wealthy people in the developed world. Do those in LMIC deserve to have pricing information for medications they may care about? My position is yes, and we have excellent sources such as MSH that
2170:
Can I ask all involved (Sandy, Colin, James) how this is helping us move forward with the RfC? If you all agree it is helpful I don't want to stand in its way and I'm glad for James' involvement as well but this seems to be continuing the conversation that has been ongoing for as long as this
939:
WAID, one concern about these prices is whether the way they are stated can have no meaning for the reader. A price "per treatment" has a clear meaning, and a price "per month" (for a drug you take long-term, which again, our source doesn't say) has a meaning. But a price "per dose" or "per xx
750:
I disagree that concentrating on a specific point of contention makes the discussion less powerful. Generally a better discussion ensues from focusing on one thing at a time, with more in-depth follow-up occurring. It's not like there's only one opportunity to gather information, so it isn't
2209:
I agree per comment I made above, though this has at least provided an excellent example of when I say many of the prices are incorrect, we aren't just talking rounding errors from choosing a 30-day month! "Some of our article prices are incorrect by a factor of 100". Original research -:
884:. The previous ones seemed to imply that commenters should comment only in one section. I would omit the sentence starting with "You can put all of your ideas in one section..." I think it makes more sense to have people separate their comments on different areas into different sections.
553:
weight, reliability of source, etc, and no sign that is a problem with editors. The only concern with some of them is that some price changes may be dated and folk need to keep an eye on the article to ensure we are no longer saying the price is $ XXX,XXX when it is now just $ X,XXX. --
771:
We had a discussion before about whether to resolve all this in one go, or to have followup RFC(s). Tryptofish was very keen to do it in one go. WAID's RFC explicitly says this will not necessarily be resolved in one go. I think it is too hard to resolve in one go, because there are
1549:
consensus that we should provide prices in dollars and pence and then excuse our original research random results by saying the prices are only meant to be accurate to two orders of magnitude and our readers are bright enough to know that. But you can try that claim at the RFC. --
380:. I am happy with either of the 4 suggestions. 3D gets to the specifics which may be useful. There are many potential ways to present pricing information and I personally am not particularly attached to any single one. 3C does the best with respect to a high level question IMO.
912:, the reason that I took the "mostly about" and "comment anywhere" approach is that I can foresee someone trying to be "helpful" by re-factoring other people's comments (e.g., splitting off a sentence or paragraph that is on a different subject). That would be a bad outcome.
1324:
The popular press manages to determine the cost for a course of treatment "Sovaldi treatment cost $ 1,000 a pill, or $ 84,000 over 12 weeks." The
Guardian managed to determine the typical dose, the typical duration of treatment, and the rough cost per dose than do the math.
2300:
blanking a few lines from more than 500 articles (and re-blanking it again in some cases, because not everyone will notice edit summaries, etc., and assume it was an accident or otherwise not warranted), and then maybe needing to restore all of those a month or two
2006:
of how the most common source has been used. We're inviting editors to look at that and tell us how much better we can make it. That's more likely to produce informed comments than merely asking editors what they believe ought to be possible hypothetically.
1688:
information we have presented unless we do synthesis. And we do not have sources that, according to DUE WEIGHT, tell us what to present in the example of chlorthalidone. The problems in other articles are worse. This is probably why we should be respecting
612:
I agree as well. These are not examples of what is generally being disputed. They might be used as examples that are far better than those under dispute. If in later discussions we consider what is proper in article ledes, then we could bring these up again.
793:
unfortunate the editor is no longer participating. I understand, though, that others are not as worried about the quality of feedback. If the key participants can agree upon the critical issues to discuss and they can be put into separate sections, great!
730:
187:
1212:
What does this tell us? The paper mentions "per tablet... twice daily" and yet there is no tablet dose that is 18.75mg. This is because DDD is not actually a therapeutic dose that any patient might take. Their maths mostly work at 50mg. Looking at
1230:
The argument here is similar to saying, "doses of medications are random". Please note they are not. There are well accepted dosage ranges. Do we need a RfC to ask "are dosages of medications random" as that is the argument you are making?
1157:
This source converts the MSH data into price per year with "Carvedilol is listed on the Management Sciences for Health International Drug Price Indicator Guide with average price per tablet of $ 0.20 or $ 144 per year for twice daily
656:
With discussion in multiple sections now, and after six weeks at this (while trying to move on to regular editing), I may be losing the plot. I am looking at and responding to the samples just above, in this section, that are
1980:"Do not include dose or titration information except when they are extensively discussed by secondary sources, necessary for the discussion in the article, or when listing equivalent doses between different pharmaceuticals"
1314:
I guess the question is do we have a fundamental disagreement? Do you believe it is possible to provide a rough estimate of the cost of a medication in LMIC or other region of the world? This can be broken down into two
116:
112:
98:
90:
85:
73:
68:
63:
2001:
99% of Wikipedians, no matter what their beliefs are. But I don't think that asking about uninvolved, non-expert editors' beliefs helps those editors help us. The current RFC draft is essentially three
1774:
question? We have not, throughout these discussions, seen one straightforward example of drug price information from the sources used in over 500 articles that we can all agree does not involve SYNTH.
833:
1940:
RfC are we allowed to multiple the "typical dosage range per day of a medication in adults as used for a specific purpose" by the "price per dose" to get the cost per day for a specific purpose?
2250:
was apparently rewarded. Generally speaking, when it becomes apparent that a large-scale change was not clearly supported by consensus, especially when it was also against policy, it should be
708:
If that's the locus for which the first RfC is intended to gather more viewpoints, then perhaps the main question in your proposed draft could focus more attention on this aspect of the issue?
2525:
No I left this open because it seemed to range beyond jsut the RfC question. DDD is obviously an essential part of the debate but it is only indirectly covered (by design) at the RfC. Best,
811:
in the edit summary (so you'll know when it's done), so you can see what one approach would look like. (Feel free to revert it after you've read it, if you don't think it will work well.)
1978:
We probably don't have an example of an existing article that talks about "typical dosage range per day of a medication in adults as used for a specific purpose" because MEDMOS has said
1470:
to 27 USD? Sure. I prescribe medications that range in price from pennies to 10,000s per dose (a million fold difference). A 2 or 4 fold difference fits well within the range of "about".
21:
2468:
for years. Yes, in which order to approach this is a dilemma. There was a point that I thought we just needed to go back to ANI, present the data developed by Colin showing how many
1653:
Now back to the question at hand. Do you believe that there is an accepted dose range for a specific indication in a typical adult? We can go with this if you do not want to use DDD.
780:. I wonder, though, if there is a way to structure discussion in the RFC so we have sections that look at different aspects. Perhaps sections for each policy? What do you think? --
2130:
get prices of $ 6.44, $ 6.61, $ 7.08 and $ 6.57 for each 10, 20, 40 and 80mg extended release tablet. Again the source does not say that I only take that once a day. See also
2151:
OK, the first example missed by a factor of 100. (Imagine our readers trying to sort that ?!?!?!) James got to choose that example, now Colin gets to choose one. Next.
1192:
the word "approximately" about as if that absolves all sins. As for the paper from 2011, it is wonderful what Google can turn up. I tried to find the record they quote.
151:
1631:
When our math is doubly wrong (12.5 vs 25 mg for chlorthalidone), we cannot say we are within a "fairly narrow dose range", and that is only one very simple example.
2044:
you are using to support your math, and shows how you have used them. Then we can talk SYNTH vs. CALC. And from there may emerge an example to be used for an RFC.
1074:
specific formulation" and "provides a rough idea of the cost differential between the two formulations of the same drug". We are using it for the first purpose.
729:. There are lots of questions people might ask themselves when looking at the source, the text and the half-a-dozen polices and guidelines linked at question at
535:
has written. This is because none of those prices are cited to the IMPPG or any other drug database, and all of the questions are about IMPPG or drug databases.
501:"Stop TB Partnership | "Stop TB Partnership's Global Drug Facility jumpstarts access to new drugs for MDR-TB with innovative public-private partnerships"
1263:
1259:
1193:
642:, focus on the locus of the dispute is great. Apologies for asking this but how are the examples in 3A - 3C not being sourced to a drug database? Best,
2306:
I prefer not to blow up people's watchlists over this. Let's do it right, once, when we have a solid agreement on what "doing it right" looks like.
1326:
776:
to discuss about this one source, without also considering problems with NADAC, BNF, Drugs.com, etc. And it would be tedious to have an each RFC for
751:
necessary to take comments on everything at once. I appreciate, though, that it's been difficult to try to reach a consensus on a specific focus.
2297:
leaving it alone, because the difference between having this content in articles for 59 months or for 61 months is basically a rounding error, or
1371:
wondering your thoughts? If either of these are false than we would all agree that it is impossible to list a price for a medication for an area.
467:
2390:
indicates that Knowledge should include at least some prices. Therefore the question is always "when and how?" rather than "always or never?"
2040:
supports the math you are using to add text cited only to a database. Let Colin pick a typical example, and you write text that incorporates
2033:
Allright, we are spinning our wheels. (Not complaining, since this is much better than the alternative, which was silence.) Let's start over.
1696:. What would be helpful to see is whether you have any example, for any drug, that discusses drug cost in a way that does not breach, IMO,
1887:
Yes we known that you think that WHO does not think that it is acceptable. But it does not appear that WHO thinks that it is unacceptable.
1731:
to convert price per dose to price per day for a typical dose or dose range which is more useful than just the price per amount by itself.
1288:
did not have SYNTH problems, and did not find one. We can save a good deal of time by having you actively engaged in those discussion,
2534:
2520:
2490:
2449:
2426:
2399:
2381:
2360:
2315:
2289:
2272:
2232:
2218:
2204:
2180:
2165:
2145:
2123:
2075:
2058:
2016:
1992:
1973:
1961:
1934:
1908:
1880:
1865:
1788:
1752:
1727:
What I am saying is we do have sources that provided accepted ranges for medications plus we have sources for DDD. It is thus a simple
1722:
1674:
1645:
1625:
1583:
1556:
1538:
1494:
1464:
1424:
1407:
1359:
1306:
1273:
1252:
1225:
1181:
1149:
1120:
1095:
1052:
1005:
989:
975:
947:
921:
901:
873:
850:
820:
802:
787:
760:
745:
717:
703:
676:
651:
622:
607:
560:
547:
401:
371:
346:
311:
286:
199:
167:
144:
2294:
This part of this question has been under discussion in various ways, off and on, since at least 2014. The practical options are:
508:
2036:
James, on this page we have been discussing a SYNTH problem. You believe this is simple math, others do not. You believe using
2115:
1953:
1900:
1857:
1744:
1666:
1617:
1486:
1399:
1351:
1244:
1173:
1141:
1087:
393:
338:
278:
2433:
1159:
51:
17:
1566:
to create a rough estimate of costs' to the start of the sentence, they'd be satisfied. Or they might tell us to use fewer
211:
Subsequent comments should be made on the appropriate discussion page. No further edits should be made to this discussion.
174:
2546:
Subsequent comments should be made on the appropriate discussion page. No further edits should be made to this discussion.
1318:
1) Do you believe it is possible to provide a typical dosage range for a medication in adults used for a specific purpose?
1061:
Subsequent comments should be made on the appropriate discussion page. No further edits should be made to this discussion.
859:
The reader is now presented with too many options, and a lengthy TOC before they are drawn into your effective writing.
2119:
2083:
1957:
1904:
1861:
1748:
1670:
1621:
1490:
1403:
1355:
1248:
1205:
1201:
1197:
1177:
1145:
1091:
397:
342:
282:
1927:
evidence this discussion is heading towards any consensus, that's why we are having the RFC, to get other voices. --
1128:
of the daily cost. Yes it does not provide "detailed" description of the cost. That is why we use the term "about".
931:
see" and just leave space for comments. It would be good to wikilink policy pages for convenience (and specifically
2420:
cases, we include prices. But most of the immediate cases aren't exceptional, and we don't include them routinely.
42:
1374:
Other questions could be is multiplying a dosage range for a purpose by the rough cost estimate by a time period
2411:
Well, sure. In exceptional cases, we should include prices. I don't think anyone would argue that, for example,
538:
I think that the conversation about prices that are not sourced to drug databases needs to be held separately.
245:
152:
Knowledge:Administrators' noticeboard/Archive317#An update on and a request for involvement at the Medicine MOS
2258:
is currently policy. If we want to have an RfC on whether it should or shouldn't be, we should have that, at
807:
I've thought about pre-structuring response sections, by way of sorting it. I'll set up a section and ping
2516:
2486:
2445:
2395:
2356:
2311:
2246:
2200:
2161:
2054:
2012:
1988:
1784:
1718:
1641:
1579:
1534:
1460:
1302:
1266:, they'd only have the 6.25mg tablet, and nobody is taking six a day unless they have no other choice. --
971:
917:
869:
846:
816:
699:
672:
603:
586:
543:
163:
2469:
1200:
tablet has a median (only) supplier price of 0.0414. At the DDD of 37.5, is six a day x 365 = $ 90. The
262:
had an agreement to get the medication for US$ 1,700 per six month for use in more than 100 countries."
2530:
2436:
for this, and even if there were, the deadline would not be "1497 days after the date was added to
2285:
2223:
I think it's been helpful in clarifying the NOR concerns, and thank Doc James for participating. --
2176:
2111:
1949:
1896:
1853:
1740:
1662:
1613:
1567:
1482:
1395:
1347:
1240:
1169:
1137:
1083:
932:
647:
389:
334:
274:
259:
195:
140:
1204:
tablet has no suppliers and a median buyer price of 0.1669. That's three a day x 365 = $ 182. The
2460:
2421:
2406:
2376:
2367:
2332:
2277:
2267:
2259:
2255:
1689:
1563:
1445:
James, it is helpful to have you fully engaged in understanding that these are complex questions
1066:
981:
909:
893:
808:
794:
765:
752:
722:
709:
566:
366:
306:
2081:
Sure lets. "In the United States, the wholesale cost per dose is less than 0.05 USD as of 2018.
2507:
2477:
2441:
2391:
2372:
2347:
2307:
2191:
2152:
2045:
2008:
1984:
1833:
1775:
1709:
1632:
1575:
1525:
1451:
1365:
1333:
1321:
2) Do you believe it is possible to provide a rough price for an amount of medication in LMIC?
1293:
962:
913:
860:
837:
827:
812:
695:
663:
639:
631:
594:
577:
539:
477:
450:
154:
1102:
2343:
1824:
1701:
985:
897:
798:
756:
713:
441:
961:
I support; no convoluted TOC, no overwhelming the reader, simple but not over-simplified.
2339:
2216:
2143:
2073:
1971:
1932:
1878:
1697:
1571:
1554:
1422:
1379:
1368:
1271:
1223:
1118:
1050:
1003:
945:
785:
743:
558:
1813:"Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C"
430:"Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C"
2526:
2503:
2473:
2281:
2241:
2228:
2186:
2172:
2103:
2003:
1997:
1966:
Example article text + source please, which gives either of those things, singular. --
1941:
1888:
1845:
1828:
1812:
1732:
1728:
1705:
1654:
1605:
1474:
1387:
1375:
1339:
1329:
1289:
1232:
1161:
1129:
1075:
954:
681:
643:
618:
500:
445:
429:
381:
353:
326:
294:
266:
191:
136:
2102:
Per the reference all doses at that point in time were less than 0.05 USD per tablet.
131:
I have notified several individual editors but also noting here that I have posted at
2387:
1383:
731:
Knowledge:Manual of Style/Medicine-related articles/RFC on pharmaceutical drug prices
532:
377:
362:
320:
302:
216:
994:
Agree that it is confused mess. I tried to restart discussion of the WAID draft at
686:
472:
132:
1979:
1126:
531:
I'd like to have that conversation, but it doesn't fit any of the questions that
590:
573:
252:
per treatment, making it the most expensive medication in the world as of 2019."
50:
If you wish to start a new discussion or revive an old one, please do so on the
2266:
should have been restored, and that was that prices are almost never included.
2135:
2131:
1214:
2212:
2139:
2069:
2065:
1967:
1928:
1874:
1692:
and not presenting these prices at all based on database sources, but that is
1550:
1545:
1418:
1267:
1219:
1114:
1046:
999:
941:
781:
739:
635:
554:
223:
1983:
whether that information is encyclopedic is a discussion for another time.)
480:
2412:
2224:
927:
627:
614:
255:
1836:
453:
1101:
James, I think our priority right now should be to launch an RFC. There's
980:
Note the table of contents can be suppressed, if desired, in any version.
2437:
325:
my though is to have one section of examples rather than three sections.
1106:
1473:
Additionally I believe our readers are smart enough to realize this.
468:"$ 2.1m Novartis gene therapy to become world's most expensive drug"
1258:
decisions and each time a different result. If the researchers had
906:
The 23 separate proposals at the GMO RFC look like an anti-pattern.
219:
wondering your thoughts on adding some more expensive ones aswell:
117:
Knowledge talk:Manual of Style/Medicine-related articles/Archive 12
113:
Knowledge talk:Manual of Style/Medicine-related articles/Archive 11
2262:(not here). Policy can change. But until and unless it does, the
2171:
dispute. If it's not helpful maybe it's best put aside for now.
2432:
your view is the one that the RFC(s) will eventually produce.
1364:
I am thinking these could be two useful questions for the RfC.
1793:
We have "As of 2016 a 12-week course of treatment costs about
1332:. WEIGHT is clear per sources such as Doctors Without Borders.
29:
953:
archive off everything here, and start over, ala cot-cob per
834:
Knowledge:Requests for comment/Genetically modified organisms
1844:
But yes lets put the SYNTH versus CALC discussion to a RfC.
299:
Adding these to which RfC draft/question? (Or all of them?)
2244:, to be honest, what's the most frustrating here is that a
565:
Agree; these appear to be examples that are compliant with
2064:
I dont' want to be accused of cherry picking. James cites
1811:
Hill A, Simmons B, Gotham D, Fortunak J (January 2016).
428:
Hill A, Simmons B, Gotham D, Fortunak J (January 2016).
2465:
1042:
958:
881:
856:
589:) 09:14, 14 January 2020 (UTC) Strike, update; fail
226:"As of 2016 a 12-week course of treatment costs about
2470:
editors have tried to remove this data over the years
832:, I am concerned that we avoid anything looking like
1650:
Are you saying 12.5 to 25 mg is a wide dosage range?
190:has started. All are invited to participate. Best,
2472:, and look for a new directive. That decision is
2254:, not maintained, during the discussion on it.
1841:" Not sure if you consider this SYNTH aswell.
8:
2211:random numbers. Anyway, back to the RFC. --
127:Discussion at the Administrative Noticeboard
777:
773:
726:
2088:Centers for Medicare and Medicaid Services
1827:
998:. Perhaps we can continue this there. --
444:
1700:. Then we could more accurately discuss
1328:. What you call SYNTH and NOR is simple
1209:Not quite the $ 144 they give but close.
1125:Yes the DDD only provides a "rough idea"
995:
420:
2506:did you mean to close this one, too?
572:We need a database example that meets
48:Do not edit the contents of this page.
1043:which was added to the article by you
175:User:Levivich/Drug prices RfC draft 3
7:
882:the revised section headings by Ronz
511:from the original on 16 January 2017
207:The following discussion is closed.
1570:, so that "about $ 13.50" becomes "
1041:Actually, James the first example,
774:more than enough possible questions
28:
2466:Here is what editors possibly saw
2542:The discussion above is closed.
1057:The discussion above is closed.
33:
2138:. So 5 cents or 7 dollars? --
1562:we added words like 'Using the
662:which WAID's draft does well.
476:. London. Reuters. 2019-05-25.
2434:Knowledge:There is no deadline
2386:Even the strictest reading of
1801:53,000 in the United Kingdom,
1382:and are prices of medications
234:53,000 in the United Kingdom,
133:the Administrative Noticeboard
18:Knowledge talk:Manual of Style
1:
1797:84,000 in the United States,
1103:a whole section at WHO on DDD
855:In that vein, I think we are
230:84,000 in the United States,
2535:01:05, 24 January 2020 (UTC)
2521:23:26, 23 January 2020 (UTC)
1817:Journal of Virus Eradication
1805:45,000 in Canada, and about
1053:09:37, 14 January 2020 (UTC)
1006:16:56, 17 January 2020 (UTC)
990:16:34, 17 January 2020 (UTC)
976:16:33, 17 January 2020 (UTC)
948:09:06, 17 January 2020 (UTC)
922:07:22, 17 January 2020 (UTC)
902:01:16, 17 January 2020 (UTC)
874:20:32, 16 January 2020 (UTC)
851:20:26, 16 January 2020 (UTC)
821:20:14, 16 January 2020 (UTC)
803:17:14, 16 January 2020 (UTC)
788:09:24, 16 January 2020 (UTC)
761:23:14, 15 January 2020 (UTC)
746:21:00, 15 January 2020 (UTC)
718:18:22, 15 January 2020 (UTC)
704:18:03, 15 January 2020 (UTC)
677:16:16, 15 January 2020 (UTC)
652:15:57, 15 January 2020 (UTC)
623:18:19, 14 January 2020 (UTC)
608:09:41, 14 January 2020 (UTC)
561:09:11, 14 January 2020 (UTC)
548:05:42, 14 January 2020 (UTC)
434:Journal of Virus Eradication
402:11:09, 15 January 2020 (UTC)
372:19:08, 14 January 2020 (UTC)
347:11:05, 14 January 2020 (UTC)
312:02:16, 14 January 2020 (UTC)
287:20:55, 13 January 2020 (UTC)
248:"It carries a list price of
238:45,000 in Canada, and about
200:23:10, 23 January 2020 (UTC)
168:14:21, 30 January 2020 (UTC)
2491:02:58, 7 January 2020 (UTC)
2450:19:31, 7 January 2020 (UTC)
2427:03:02, 7 January 2020 (UTC)
2400:02:54, 7 January 2020 (UTC)
2382:02:48, 7 January 2020 (UTC)
2361:02:45, 7 January 2020 (UTC)
2316:02:25, 7 January 2020 (UTC)
2290:02:11, 7 January 2020 (UTC)
2273:01:56, 7 January 2020 (UTC)
2233:19:33, 6 January 2020 (UTC)
2219:18:20, 6 January 2020 (UTC)
2205:18:06, 6 January 2020 (UTC)
2181:18:02, 6 January 2020 (UTC)
2166:16:36, 6 January 2020 (UTC)
2146:16:03, 6 January 2020 (UTC)
2132:Drugs.com Carvedilol Dosage
2124:15:47, 6 January 2020 (UTC)
2076:15:15, 6 January 2020 (UTC)
2059:15:07, 6 January 2020 (UTC)
2017:20:46, 6 January 2020 (UTC)
1993:20:20, 6 January 2020 (UTC)
1974:15:15, 6 January 2020 (UTC)
1962:14:58, 6 January 2020 (UTC)
1935:14:55, 6 January 2020 (UTC)
1909:14:53, 6 January 2020 (UTC)
1881:14:39, 6 January 2020 (UTC)
1866:14:53, 6 January 2020 (UTC)
1789:14:35, 6 January 2020 (UTC)
1753:14:27, 6 January 2020 (UTC)
1723:14:22, 6 January 2020 (UTC)
1675:14:09, 6 January 2020 (UTC)
1646:13:57, 6 January 2020 (UTC)
1626:13:51, 6 January 2020 (UTC)
1584:20:31, 6 January 2020 (UTC)
1557:14:35, 6 January 2020 (UTC)
1539:14:31, 6 January 2020 (UTC)
1495:14:14, 6 January 2020 (UTC)
1465:13:55, 6 January 2020 (UTC)
1425:13:34, 6 January 2020 (UTC)
1408:13:17, 6 January 2020 (UTC)
1360:12:55, 6 January 2020 (UTC)
1307:12:25, 6 January 2020 (UTC)
1274:13:59, 6 January 2020 (UTC)
1253:13:32, 6 January 2020 (UTC)
1226:13:25, 6 January 2020 (UTC)
1182:12:21, 6 January 2020 (UTC)
1150:12:14, 6 January 2020 (UTC)
1121:11:50, 6 January 2020 (UTC)
1096:11:19, 6 January 2020 (UTC)
145:03:45, 7 January 2020 (UTC)
2560:
2042:all of those other sources
1413:and existing medications.
570:, so are not in question.
22:Medicine-related articles
2544:Please do not modify it.
2084:"NADAC as of 2018-12-19"
1338:provides these details.
1059:Please do not modify it.
246:Onasemnogene abeparvovec
209:Please do not modify it.
1196:gives three doses. The
727:#Questions not Opinions
926:I too like the change
857:moving backwards here.
111:NOTE: Continued from
46:of past discussions.
2068:above. Try that. --
1447:even for those of us
1105:and specifically on
996:#Polishing the draft
694:developing world?"
1568:significant figures
959:THIS is the version
260:Stop TB Partnership
1564:defined daily dose
1194:Carvedilol in 2011
1067:Defined daily dose
210:
2474:above my paygrade
2425:
2410:
2380:
2371:
2271:
2136:Carvedilol Prices
1366:User:WhatamIdoing
1107:its use and abuse
725:, have a look at
250:US$ 2.125 million
208:
150:Link to archive:
104:
103:
58:
57:
52:current talk page
2551:
2513:
2483:
2464:
2424:
2404:
2379:
2365:
2353:
2336:
2270:
2197:
2158:
2108:
2098:
2096:
2094:
2051:
1981:
1946:
1893:
1850:
1840:
1831:
1808:
1804:
1800:
1796:
1781:
1737:
1715:
1659:
1638:
1610:
1531:
1479:
1457:
1392:
1344:
1299:
1260:searched in 2010
1237:
1166:
1134:
1080:
968:
866:
843:
831:
669:
600:
583:
521:
520:
518:
516:
497:
491:
490:
488:
487:
464:
458:
457:
448:
425:
386:
370:
369:
357:
331:
324:
310:
309:
298:
271:
258:"As of 2016 the
251:
241:
237:
233:
229:
160:
82:
60:
59:
37:
36:
30:
2559:
2558:
2554:
2553:
2552:
2550:
2549:
2548:
2547:
2511:
2481:
2458:
2351:
2330:
2264:status quo ante
2195:
2156:
2104:
2092:
2090:
2082:
2049:
2031:
2004:worked examples
1942:
1889:
1846:
1810:
1806:
1802:
1798:
1794:
1779:
1733:
1713:
1655:
1636:
1606:
1572:on the order of
1529:
1475:
1455:
1388:
1369:User:Tryptofish
1340:
1297:
1233:
1162:
1130:
1076:
1071:
1063:
1062:
966:
864:
841:
825:
667:
598:
581:
526:
525:
524:
514:
512:
499:
498:
494:
485:
483:
466:
465:
461:
427:
426:
422:
382:
365:
360:
351:
327:
318:
305:
300:
292:
267:
249:
239:
235:
231:
227:
213:
204:
203:
202:
183:
178:
158:
129:
78:
34:
26:
25:
24:
12:
11:
5:
2557:
2555:
2541:
2540:
2539:
2538:
2537:
2501:
2500:
2499:
2498:
2497:
2496:
2495:
2494:
2493:
2456:
2455:
2454:
2453:
2452:
2323:
2322:
2321:
2320:
2319:
2318:
2304:
2303:
2302:
2298:
2239:
2238:
2237:
2236:
2235:
2149:
2148:
2079:
2078:
2030:
2027:
2026:
2025:
2024:
2023:
2022:
2021:
2020:
2019:
1998:User:Doc James
1924:
1923:
1922:
1921:
1920:
1919:
1918:
1917:
1916:
1915:
1914:
1913:
1912:
1911:
1870:
1869:
1868:
1842:
1762:
1761:
1760:
1759:
1758:
1757:
1756:
1755:
1680:
1679:
1678:
1677:
1651:
1601:
1600:
1599:
1598:
1597:
1596:
1595:
1594:
1593:
1592:
1591:
1590:
1589:
1588:
1587:
1586:
1541:
1508:
1507:
1506:
1505:
1504:
1503:
1502:
1501:
1500:
1499:
1498:
1497:
1471:
1434:
1433:
1432:
1431:
1430:
1429:
1428:
1427:
1414:
1372:
1335:
1322:
1319:
1316:
1285:
1284:
1283:
1282:
1281:
1280:
1279:
1278:
1277:
1276:
1210:
1155:
1154:
1153:
1152:
1110:
1070:
1064:
1056:
1039:
1038:
1037:
1036:
1035:
1034:
1033:
1032:
1031:
1030:
1029:
1028:
1027:
1026:
1025:
1024:
1023:
1022:
1021:
1020:
1019:
1018:
1017:
1016:
1015:
1014:
1013:
1012:
1011:
1010:
1009:
1008:
992:
937:
924:
907:
889:
885:
878:
877:
876:
769:
691:
610:
550:
536:
523:
522:
505:www.stoptb.org
492:
459:
419:
418:
414:
413:
412:
411:
410:
409:
408:
407:
406:
405:
404:
264:
263:
253:
243:
242:500 in India."
214:
205:
185:
184:
181:
180:
179:
177:
172:
171:
170:
128:
125:
124:
123:
122:
121:
120:
119:
102:
101:
96:
93:
88:
83:
76:
71:
66:
56:
55:
38:
27:
15:
14:
13:
10:
9:
6:
4:
3:
2:
2556:
2545:
2536:
2532:
2528:
2524:
2523:
2522:
2518:
2514:
2510:
2505:
2502:
2492:
2488:
2484:
2480:
2475:
2471:
2467:
2462:
2461:Seraphimblade
2457:
2451:
2447:
2443:
2439:
2435:
2430:
2429:
2428:
2423:
2422:Seraphimblade
2419:
2414:
2408:
2407:edit conflict
2403:
2402:
2401:
2397:
2393:
2389:
2385:
2384:
2383:
2378:
2377:Seraphimblade
2374:
2369:
2368:edit conflict
2364:
2363:
2362:
2358:
2354:
2350:
2345:
2341:
2334:
2333:Seraphimblade
2329:
2328:
2327:
2326:
2325:
2324:
2317:
2313:
2309:
2305:
2299:
2296:
2295:
2293:
2292:
2291:
2287:
2283:
2279:
2278:Seraphimblade
2276:
2275:
2274:
2269:
2268:Seraphimblade
2265:
2261:
2257:
2253:
2249:
2248:
2247:fait accompli
2243:
2240:
2234:
2230:
2226:
2222:
2221:
2220:
2217:
2214:
2208:
2207:
2206:
2202:
2198:
2194:
2188:
2185:
2184:
2183:
2182:
2178:
2174:
2168:
2167:
2163:
2159:
2155:
2147:
2144:
2141:
2137:
2133:
2128:
2127:
2126:
2125:
2121:
2117:
2113:
2109:
2107:
2100:
2089:
2085:
2077:
2074:
2071:
2067:
2063:
2062:
2061:
2060:
2056:
2052:
2048:
2043:
2039:
2038:other sources
2034:
2028:
2018:
2014:
2010:
2005:
1999:
1996:
1995:
1994:
1990:
1986:
1977:
1976:
1975:
1972:
1969:
1965:
1964:
1963:
1959:
1955:
1951:
1947:
1945:
1939:
1938:
1937:
1936:
1933:
1930:
1910:
1906:
1902:
1898:
1894:
1892:
1886:
1885:
1884:
1883:
1882:
1879:
1876:
1871:
1867:
1863:
1859:
1855:
1851:
1849:
1843:
1838:
1835:
1830:
1826:
1822:
1818:
1814:
1809:500 in India.
1792:
1791:
1790:
1786:
1782:
1778:
1772:
1771:
1770:
1769:
1768:
1767:
1766:
1765:
1764:
1763:
1754:
1750:
1746:
1742:
1738:
1736:
1730:
1726:
1725:
1724:
1720:
1716:
1712:
1707:
1703:
1699:
1695:
1691:
1686:
1685:
1684:
1683:
1682:
1681:
1676:
1672:
1668:
1664:
1660:
1658:
1652:
1649:
1648:
1647:
1643:
1639:
1635:
1630:
1629:
1628:
1627:
1623:
1619:
1615:
1611:
1609:
1585:
1581:
1577:
1573:
1569:
1565:
1560:
1559:
1558:
1555:
1552:
1547:
1542:
1540:
1536:
1532:
1528:
1522:
1521:
1520:
1519:
1518:
1517:
1516:
1515:
1514:
1513:
1512:
1511:
1510:
1509:
1496:
1492:
1488:
1484:
1480:
1478:
1472:
1468:
1467:
1466:
1462:
1458:
1454:
1448:
1444:
1443:
1442:
1441:
1440:
1439:
1438:
1437:
1436:
1435:
1426:
1423:
1420:
1415:
1411:
1410:
1409:
1405:
1401:
1397:
1393:
1391:
1385:
1381:
1377:
1373:
1370:
1367:
1363:
1362:
1361:
1357:
1353:
1349:
1345:
1343:
1336:
1334:
1331:
1327:
1323:
1320:
1317:
1313:
1312:
1311:
1310:
1309:
1308:
1304:
1300:
1296:
1291:
1275:
1272:
1269:
1265:
1261:
1256:
1255:
1254:
1250:
1246:
1242:
1238:
1236:
1229:
1228:
1227:
1224:
1221:
1216:
1211:
1207:
1203:
1199:
1195:
1190:
1189:
1188:
1187:
1186:
1185:
1184:
1183:
1179:
1175:
1171:
1167:
1165:
1160:
1151:
1147:
1143:
1139:
1135:
1133:
1127:
1124:
1123:
1122:
1119:
1116:
1111:
1108:
1104:
1100:
1099:
1098:
1097:
1093:
1089:
1085:
1081:
1079:
1068:
1065:
1060:
1055:
1054:
1051:
1048:
1044:
1007:
1004:
1001:
997:
993:
991:
987:
983:
979:
978:
977:
973:
969:
965:
960:
956:
951:
950:
949:
946:
943:
938:
934:
929:
925:
923:
919:
915:
911:
908:
905:
904:
903:
899:
895:
892:current one.
890:
886:
883:
879:
875:
871:
867:
863:
858:
854:
853:
852:
848:
844:
840:
835:
829:
824:
823:
822:
818:
814:
810:
806:
805:
804:
800:
796:
791:
790:
789:
786:
783:
779:
775:
770:
767:
764:
763:
762:
758:
754:
749:
748:
747:
744:
741:
736:
732:
728:
724:
721:
720:
719:
715:
711:
707:
706:
705:
701:
697:
692:
689:
688:
683:
680:
679:
678:
674:
670:
666:
660:
655:
654:
653:
649:
645:
641:
637:
633:
629:
626:
625:
624:
620:
616:
611:
609:
605:
601:
597:
592:
588:
584:
580:
575:
571:
568:
564:
563:
562:
559:
556:
551:
549:
545:
541:
537:
534:
530:
529:
528:
527:
510:
506:
502:
496:
493:
482:
479:
475:
474:
469:
463:
460:
455:
452:
447:
443:
439:
435:
431:
424:
421:
417:
403:
399:
395:
391:
387:
385:
379:
378:User:Levivich
375:
374:
373:
368:
364:
355:
350:
349:
348:
344:
340:
336:
332:
330:
322:
317:
316:
315:
314:
313:
308:
304:
296:
291:
290:
289:
288:
284:
280:
276:
272:
270:
261:
257:
254:
247:
244:
225:
222:
221:
220:
218:
217:User:Levivich
212:
201:
197:
193:
189:
176:
173:
169:
165:
161:
157:
153:
149:
148:
147:
146:
142:
138:
134:
126:
118:
114:
110:
109:
108:
107:
106:
105:
100:
97:
94:
92:
89:
87:
84:
81:
77:
75:
72:
70:
67:
65:
62:
61:
53:
49:
45:
44:
39:
32:
31:
23:
19:
2543:
2508:
2478:
2442:WhatamIdoing
2417:
2392:WhatamIdoing
2373:SandyGeorgia
2348:
2308:WhatamIdoing
2263:
2251:
2245:
2192:
2169:
2153:
2150:
2105:
2101:
2091:. Retrieved
2087:
2080:
2046:
2041:
2037:
2035:
2032:
2009:WhatamIdoing
1985:WhatamIdoing
1943:
1925:
1890:
1847:
1823:(1): 28–31.
1820:
1816:
1776:
1734:
1710:
1693:
1656:
1633:
1607:
1602:
1576:WhatamIdoing
1526:
1476:
1452:
1446:
1389:
1341:
1294:
1286:
1262:rather than
1234:
1163:
1156:
1131:
1077:
1072:
1058:
1040:
963:
933:WP:NOTPRICES
914:WhatamIdoing
861:
838:
828:WhatamIdoing
813:WhatamIdoing
734:
696:WhatamIdoing
687:The Guardian
685:
664:
658:
640:WhatamIdoing
632:SandyGeorgia
595:
593:per Colin.
578:
569:
540:WhatamIdoing
513:. Retrieved
504:
495:
484:. Retrieved
473:The Guardian
471:
462:
440:(1): 28–31.
437:
433:
423:
415:
383:
328:
268:
265:
215:
206:
182:RFC LAUNCHED
155:
130:
79:
47:
41:
2418:exceptional
2256:WP:NOPRICES
2093:22 December
1690:WP:NOTPRICE
910:User:Isaacl
567:WP:NOTPRICE
40:This is an
2066:Carvedilol
1694:my opinion
1546:Carvedilol
1158:treatment"
515:15 January
486:2019-05-25
416:References
224:Sofosbuvir
99:Archive 17
91:Archive 15
86:Archive 14
80:Archive 13
74:Archive 12
69:Archive 11
64:Archive 10
2527:Barkeep49
2504:Barkeep49
2413:I Am Rich
2344:WP:PRICES
2282:Barkeep49
2242:Barkeep49
2187:Barkeep49
2173:Barkeep49
2106:Doc James
1944:Doc James
1891:Doc James
1848:Doc James
1735:Doc James
1702:WP:WEIGHT
1657:Doc James
1608:Doc James
1477:Doc James
1390:Doc James
1342:Doc James
1235:Doc James
1215:Drugs.com
1164:Doc James
1132:Doc James
1078:Doc James
955:Barkeep49
880:I prefer
778:all these
682:Barkeep49
644:Barkeep49
481:0261-3077
384:Doc James
354:Doc James
329:Doc James
295:Doc James
269:Doc James
256:Delamanid
192:Barkeep49
137:Barkeep49
2438:diazepam
2340:WP:PRICE
2252:reversed
2116:contribs
1954:contribs
1901:contribs
1858:contribs
1837:27482432
1745:contribs
1708:issues.
1698:WP:SYNTH
1667:contribs
1618:contribs
1487:contribs
1400:contribs
1380:WP:SYNTH
1352:contribs
1245:contribs
1174:contribs
1142:contribs
1088:contribs
533:Levivich
509:Archived
454:27482432
394:contribs
376:Ah okay
339:contribs
321:Levivich
279:contribs
20: |
2512:Georgia
2482:Georgia
2352:Georgia
2196:Georgia
2157:Georgia
2050:Georgia
1829:4946692
1780:Georgia
1729:WP:CALC
1714:Georgia
1706:WP:LEAD
1637:Georgia
1530:Georgia
1456:Georgia
1376:WP:CALC
1330:WP:CALC
1298:Georgia
967:Georgia
865:Georgia
842:Georgia
668:Georgia
599:Georgia
582:Georgia
446:4946692
159:Georgia
43:archive
2388:WP:NOT
2301:later.
2260:WT:NOT
2029:Reboot
1384:WP:DUE
1315:parts:
1202:12.5mg
1198:6.25mg
982:isaacl
894:isaacl
795:isaacl
766:isaacl
753:isaacl
723:isaacl
710:isaacl
2509:Sandy
2479:Sandy
2349:Sandy
2213:Colin
2193:Sandy
2154:Sandy
2140:Colin
2120:email
2070:Colin
2047:Sandy
1968:Colin
1958:email
1929:Colin
1905:email
1875:Colin
1862:email
1777:Sandy
1749:email
1711:Sandy
1671:email
1634:Sandy
1622:email
1551:Colin
1527:Sandy
1491:email
1453:Sandy
1419:Colin
1404:email
1356:email
1295:Sandy
1290:James
1268:Colin
1249:email
1220:Colin
1178:email
1146:email
1115:Colin
1092:email
1069:(DDD)
1047:Colin
1000:Colin
964:Sandy
942:Colin
862:Sandy
839:Sandy
782:Colin
740:Colin
665:Sandy
636:Colin
596:Sandy
579:Sandy
555:Colin
398:email
363:Leviv
343:email
303:Leviv
283:email
156:Sandy
16:<
2531:talk
2517:Talk
2487:Talk
2446:talk
2440:".
2396:talk
2357:Talk
2312:talk
2286:talk
2229:talk
2225:Ronz
2201:Talk
2177:talk
2162:Talk
2134:and
2112:talk
2095:2018
2055:Talk
2013:talk
1989:talk
1950:talk
1897:talk
1854:talk
1834:PMID
1807:US$
1803:US$
1799:US$
1795:US$
1785:Talk
1741:talk
1719:Talk
1704:and
1663:talk
1642:Talk
1614:talk
1580:talk
1535:Talk
1483:talk
1461:Talk
1396:talk
1348:talk
1303:Talk
1264:2011
1241:talk
1206:25mg
1170:talk
1138:talk
1084:talk
986:talk
972:Talk
928:Ronz
918:talk
898:talk
870:Talk
847:Talk
817:talk
799:talk
757:talk
735:lots
714:talk
700:talk
673:Talk
648:talk
628:Ronz
619:talk
615:Ronz
604:Talk
591:WP:V
587:Talk
574:WP:V
544:talk
517:2017
478:ISSN
451:PMID
390:talk
335:talk
275:talk
240:US$
236:US$
232:US$
228:US$
196:talk
186:The
164:Talk
141:talk
115:and
2519:)
2489:)
2359:)
2210:-->
2203:)
2164:)
2057:)
1825:PMC
1787:)
1721:)
1644:)
1537:)
1463:)
1378:or
1305:)
974:)
957:.
872:)
849:)
809:you
675:)
659:not
606:)
576:.
442:PMC
367:ich
307:ich
188:RfC
166:)
2533:)
2448:)
2398:)
2342:,
2314:)
2288:)
2231:)
2179:)
2122:)
2118:·
2114:·
2099:"
2086:.
2015:)
1991:)
1960:)
1956:·
1952:·
1907:)
1903:·
1899:·
1864:)
1860:·
1856:·
1832:.
1819:.
1815:.
1751:)
1747:·
1743:·
1673:)
1669:·
1665:·
1624:)
1620:·
1616:·
1582:)
1493:)
1489:·
1485:·
1406:)
1402:·
1398:·
1358:)
1354:·
1350:·
1251:)
1247:·
1243:·
1180:)
1176:·
1172:·
1148:)
1144:·
1140:·
1094:)
1090:·
1086:·
988:)
920:)
900:)
819:)
801:)
759:)
716:)
702:)
650:)
638:,
634:,
630:,
621:)
613:--
546:)
507:.
503:.
470:.
449:.
436:.
432:.
400:)
396:·
392:·
361:–
345:)
341:·
337:·
301:–
285:)
281:·
277:·
198:)
143:)
135:.
95:→
2529:(
2515:(
2485:(
2463::
2459:@
2444:(
2409:)
2405:(
2394:(
2370:)
2366:(
2355:(
2335::
2331:@
2310:(
2284:(
2227:(
2215:°
2199:(
2175:(
2160:(
2142:°
2110:(
2097:.
2072:°
2053:(
2011:(
1987:(
1970:°
1948:(
1931:°
1895:(
1877:°
1852:(
1839:.
1821:2
1783:(
1739:(
1717:(
1661:(
1640:(
1612:(
1578:(
1553:°
1533:(
1481:(
1459:(
1421:°
1394:(
1386:.
1346:(
1301:(
1270:°
1239:(
1222:°
1168:(
1136:(
1117:°
1082:(
1049:°
1002:°
984:(
970:(
944:°
916:(
896:(
868:(
845:(
830::
826:@
815:(
797:(
784:°
755:(
742:°
712:(
698:(
690:.
671:(
646:(
617:(
602:(
585:(
557:°
542:(
519:.
489:.
456:.
438:2
388:(
356::
352:@
333:(
323::
319:@
297::
293:@
273:(
194:(
162:(
139:(
54:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.